Do not treat from CIS onset: Evaluate disease course and prognosis first-Yes

Reem F. Bunyan, Sean J. Pittock

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

As physicians how do we counsel our patients with clinically isolated syndrome (CIS) when they ask, 'what is the benefit of injecting disease-modifying agents (DMAs) over many years? What disability will they prevent in my future?' In this debate, we will provide three core points supporting the concept that a watchful waiting approach (annual neurological evaluation and magnetic resonance imaging of the head (with gadolinium) at least for the first few years after diagnosis) for most patients with CIS represents appropriate medical care.

Original languageEnglish (US)
Pages (from-to)391-393
Number of pages3
JournalMultiple Sclerosis Journal
Volume18
Issue number4
DOIs
StatePublished - Apr 2012

Keywords

  • beta-interferon
  • demyelination
  • disease-modifying therapies
  • glatiramer acetate
  • multiple sclerosis
  • outcome measurement

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Do not treat from CIS onset: Evaluate disease course and prognosis first-Yes'. Together they form a unique fingerprint.

Cite this